On Wednesday, JPMorgan adjusted its outlook on Elevance (NYSE:ELV), lowering the price target to $548 from the previous $655, while continuing to endorse the stock with an Overweight rating. The firm's analysis highlighted Elevance's strong market presence, noting it "owns the most recognizable national brand and operates with leading market share in its commercial licensed BCBS markets."
The maintained Overweight rating is based on the expectation of increased earnings per share (EPS) growth through 2025, driven by margin expansion opportunities. The company is expected to enhance Commercial margins through pricing strategies and a deeper penetration of specialty products. This strategy aims to reduce the profitability gap between Administrative Services Only (ASO) and fully insured plans from the current 4:1 ratio closer to 3:1.
In the Government sector, JPMorgan anticipates a significant uplift in Medicare Advantage margins in 2023, which should help to mitigate challenges arising from Medicaid redeterminations. Despite a slight decline in Star ratings anticipated for 2024, Elevance is expected to remain above the industry average, potentially allowing the company to capture additional market share in a tough rate environment.
In other recent news, Elevance Health Inc. has seen several adjustments to its stock price targets following the release of its third-quarter earnings for 2024. TD Cowen lowered its price target from $589 to $484, while projecting a 6% EPS growth for 2025.
Similarly, Jefferies cut its price target from $600 to $529, citing challenges in the company's financial outlook. Leerink Partners also reduced its price target from $620 to $515, maintaining an Outperform rating. RBC Capital Markets followed suit, lowering its price target from $585 to $478, while Truist Securities cut its price target from $620 to $520.
Despite these adjustments, all firms maintained positive ratings on Elevance's stock, reflecting confidence in the company's future performance. The revised targets come in the wake of Elevance's lower than expected Q3 2024 earnings, with an adjusted diluted EPS of $8.37, due to increased medical costs in its Medicaid business. However, the company reported a 5% increase in total operating revenue, reaching $44.7 billion, alongside a significant growth in commercial membership by nearly 600,000 year-over-year.
InvestingPro Insights
Elevance Health's financial metrics and market position align with JPMorgan's Overweight rating, despite the lowered price target. According to InvestingPro data, Elevance boasts a market capitalization of $96.66 billion and a P/E ratio of 15.06, suggesting a relatively attractive valuation for a company of its size in the healthcare sector. The company's revenue growth of 3.2% over the last twelve months, coupled with a robust EBITDA growth of 13.51%, indicates steady financial performance.
InvestingPro Tips highlight Elevance's strong financial position and shareholder-friendly policies. The company holds more cash than debt on its balance sheet, which provides financial flexibility to pursue growth opportunities and weather potential market downturns. Additionally, Elevance has raised its dividend for 14 consecutive years, demonstrating a commitment to returning value to shareholders. This aligns with JPMorgan's positive outlook on the company's earnings growth potential.
It's worth noting that Elevance's stock is currently trading near its 52-week low and has experienced a significant decline over the past week and month. This recent price action could present an opportunity for investors who share JPMorgan's bullish outlook on the company's future performance.
For investors seeking a more comprehensive analysis, InvestingPro offers 15 additional tips on Elevance Health, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.